Capital Group Private Client Services Inc. Takes $11.69 Million Position in Horizon Therapeutics Public Limited (NASDAQ:HZNP)

Capital Group Private Client Services Inc. acquired a new stake in Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating) in the 1st quarter, Holdings Channel.com reports. The fund acquired 111,127 shares of the biopharmaceutical company’s stock, valued at approximately $11,692,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Johnson Financial Group Inc. bought a new stake in Horizon Therapeutics Public in the 4th quarter valued at $25,000. UMB Bank N A MO acquired a new stake in shares of Horizon Therapeutics Public during the fourth quarter valued at about $34,000. Covestor Ltd bought a new position in shares of Horizon Therapeutics Public during the fourth quarter worth about $37,000. Citizens National Bank Trust Department bought a new position in shares of Horizon Therapeutics Public during the fourth quarter worth about $38,000. Finally, Tcwp LLC bought a new stake in Horizon Therapeutics Public in the first quarter worth approximately $41,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. The Goldman Sachs Group cut their target price on Horizon Therapeutics Public from $164.00 to $144.00 and set a “buy” rating on the stock in a research report on Thursday, August 4th. SVB Leerink lowered Horizon Therapeutics Public from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 4th. TheStreet lowered Horizon Therapeutics Public from a “b” rating to a “c+” rating in a research note on Tuesday, August 16th. StockNews.com lowered Horizon Therapeutics Public from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Finally, BMO Capital Markets cut their price objective on Horizon Therapeutics Public from $145.00 to $117.00 and set an “outperform” rating for the company in a report on Thursday, August 4th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Horizon Therapeutics Public has a consensus rating of “Moderate Buy” and a consensus price target of $117.22.

Horizon Therapeutics Public Price Performance

HZNP opened at $66.09 on Friday. Horizon Therapeutics Public Limited has a 1 year low of $57.84 and a 1 year high of $120.54. The business’s 50-day moving average is $71.68 and its two-hundred day moving average is $88.14. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.05 and a quick ratio of 3.79. The firm has a market capitalization of $15.23 billion, a PE ratio of 20.40, a price-to-earnings-growth ratio of 1.64 and a beta of 1.21.

Horizon Therapeutics Public (NASDAQ:HZNPGet Rating) last announced its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $1.07 earnings per share for the quarter, missing the consensus estimate of $1.36 by ($0.29). Horizon Therapeutics Public had a return on equity of 27.90% and a net margin of 20.06%. The company had revenue of $876.40 million for the quarter, compared to analyst estimates of $938.82 million. During the same period in the prior year, the business posted $1.62 earnings per share. Horizon Therapeutics Public’s revenue for the quarter was up 5.3% on a year-over-year basis. Research analysts anticipate that Horizon Therapeutics Public Limited will post 4.27 earnings per share for the current fiscal year.

Insider Transactions at Horizon Therapeutics Public

In other news, EVP Andy Pasternak sold 4,850 shares of the company’s stock in a transaction dated Friday, July 29th. The shares were sold at an average price of $82.57, for a total value of $400,464.50. Following the completion of the sale, the executive vice president now directly owns 34,047 shares of the company’s stock, valued at $2,811,260.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Horizon Therapeutics Public news, EVP Sean M. Clayton acquired 745 shares of the company’s stock in a transaction dated Thursday, August 4th. The stock was bought at an average price of $66.67 per share, with a total value of $49,669.15. Following the completion of the transaction, the executive vice president now directly owns 745 shares of the company’s stock, valued at $49,669.15. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Andy Pasternak sold 4,850 shares of the firm’s stock in a transaction on Friday, July 29th. The stock was sold at an average price of $82.57, for a total transaction of $400,464.50. Following the transaction, the executive vice president now directly owns 34,047 shares of the company’s stock, valued at $2,811,260.79. The disclosure for this sale can be found here. In the last three months, insiders sold 5,022 shares of company stock valued at $415,089. Insiders own 2.50% of the company’s stock.

About Horizon Therapeutics Public

(Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.

Further Reading

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating).

Institutional Ownership by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.